Company Overview

Update
Founded:
1999
Headquarters:
San Diego, CA
Funding:
$55.6M
Categories:
Biotechnology
Description:
ViaCyte is a preclinical therapeutic company focused on a product which can free type-1 and 2 diabetes patients from insulin dependence.

Detailed Description

Update

ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Current Team (3)

Update

Board Members and Advisors (1)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    3550 General Atomics Court

    San Diego, CA 92121

    USA

Images (1)

Update
  • 9a94e5082c5ad26d196d0af141829c92